Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02326844
Title BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment
Recruitment Terminated
Gender female
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

ovarian cancer

Therapies

Talazoparib

Age Groups: adult
Covered Countries USA


No variant requirements are available.